US 12,281,115 B2
Azaindole rock inhibitors
Thomas Maxwell Kaiser, Durham, NC (US)
Assigned to Avicenna Biosciences, Inc., Durham, NC (US)
Filed by Avicenna Biosciences, Inc., Durham, NC (US)
Filed on Oct. 14, 2024, as Appl. No. 18/914,975.
Application 18/914,975 is a continuation of application No. 18/610,041, filed on Mar. 19, 2024, granted, now 12,116,366.
Application 18/610,041 is a continuation of application No. PCT/US2023/086402, filed on Dec. 29, 2023.
Claims priority of provisional application 63/436,408, filed on Dec. 30, 2022.
Prior Publication US 2025/0092038 A1, Mar. 20, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/437 (2006.01); A61K 47/20 (2006.01); A61K 47/38 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 31/437 (2013.01); A61K 47/20 (2013.01); A61K 47/38 (2013.01)] 30 Claims
 
1. A compound of Formula:

OG Complex Work Unit Chemistry
wherein:
R1 and R2 are independently selected from the group consisting of hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, and halogen.